entertainment -WSS

entertainment

author：Wikipedia 2025-09-27 09:46:42 - browse：85523

A collage illustration with a patient in the center with a hand to the left administering treatment and a doctor in the background. -- health tech coverage from STAT — Katy Lemay for STAT

The makers of minimally invasive surgical devices seemed poised to capture a wide swath of the obesity treatment market. Patients needed an option that lay between the two treatment extremes: cutting open the abdomen to perform permanent bariatric surgery, or changing your diet or exercise routine.

Then, a new class of weight loss medications that successfully mimic the feeling of fullness hit the market, and the landscape changed.

“It turns out that what came along — before those endoscopic devices have really matured — is these new drugs,” said Lee Kaplan, director of Massachusetts General’s obesity institute. Since the Food and Drug Administration approved Novo Nordisk’s Wegovy in 2021, it and similar drugs that followed have swiftly captured the public’s interest — and are on their way to generating billions of dollars in sales.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： A new nitrogen execution bill also undermines medical licensing

WSS

STAT readers on older presidents, polypills, Medicare, and more

Eli Lilly expects to double planned employment in Boston center

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

A solution to the after

With competition flaring, obesity drug hits goal in liver disease study

entertainment

entertainment

hotspot

The high cost of giving birth even with insurance

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Malaria cases in Florida and Texas: Here’s what you need to know

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

23andMe had bad news about my health. I wish a person had delivered it

A new nitrogen execution bill also undermines medical licensing

23andMe had bad news about my health. I wish a person had delivered it

STAT readers on older presidents, polypills, Medicare, and more

Psychedelics group wrestles with new pharma identity

Medicare reduced heart disease by changing how it pays doctors

leisure time

First Opinion Podcast: Long Covid needs a new approach

STAT Summit: How a Chicago ER doctor tackles gun violence

STAT Readout Newsletter: Today's biggest biotech updates

STAT readers on older presidents, polypills, Medicare, and more

A solution to the after

Solve the antibiotic resistance crisis with preventive drugs

explore

leisure time

focus

Wikipedia